CARS: Citrulline and Arginase Activity in Severe Sepsis and Septic Shock
Study Details
Study Description
Brief Summary
Sepsis is an acute pathology defined as an inappropriate response of the host to infection, resulting in the onset of organ failure (Quick SOFA ≥2, or SOFA ≥2). Septic shock is a sepsis associated with an elevation of lactate ≥ 2 mmol / l and an arterial hypotension requiring vasoactive drugs. Several studies highlighted that sepsis is associated with a plasma L-arginine deficiency. This deficiency induces a lower availability of L-arginine for multiple metabolic pathways including those involved in the synthesis of nitric oxide (NO) in the vascular endothelium via NO synthase. NO is the main endogenous vasodilator mediator, a lower synthesis induces a vascular and endothelial dysfunction that can promote the occurrence of an organic dysfunction during sepsis. Decrease in available NO was confirmed in patients with sepsis and appears correlated with severity.
L-arginine deficiency can have multiple origins:
-
L-arginine deficiency resulting from a decrease in endogenous production from citrulline synthesized by the enterocytes. Such enterocyte dysfunction has been confirmed in patients with sepsis and is characterized biologically by elevated plasma levels of I-FABP (intestinal fatty acid binding protein - enterocyte-specific protein, cytolysis marker) and lower than that of citrulline (hypocitrullinemia, marker of lower activity).
-
L-arginine deficiency may also result from a catabolism increase via arginase activity increased. This ubiquitous enzyme, having 2 isoforms (Arg1 and Arg2), allows the synthesis of urea and ornithine from L-arginine. An increase in arginase activity would decrease the available reserves of L-arginine for NO synthesis.
The objectives of this work is to evaluate, in patients with severe sepsis or septic shock, the prognostic value of the plasma arginase activity and the plasma expression of 2 isoforms Arg1 and Arg2, their kinetics, and the link between activity / expression of arginase and enterocyte dysfunction.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- prognostic value of plasma arginase activity and expression at ICU admission in patients with severe sepsis or septic shock [28 days]
activity / expression of plasma arginase at ICU admission and 28-day mortality rate from admission to intensive care
Secondary Outcome Measures
- activity / expression kinetic of plasma arginase [during the first 7 days of ICU admission]
3 points kinetic : admission, day 3 and day 7
- prognostic value of enterocyte damage [28 days]
at ICU admission and 28-day mortality rate from admission to intensive care
Eligibility Criteria
Criteria
Inclusion Criteria:
-
18 years old or older
-
Patient admitted to ICU
-
Diagnosis, suspected or confirmed, of severe sepsis or septic shock
-
Expected ICU stay of at least 2 days
-
Affiliation to a social security system or recipient of a such system
-
Signed informed consent
Exclusion Criteria:
-
Pregnancy
-
Chronic intestinal pathology
-
Chronic renal failure defined by creatinine clearance <50 ml / min / 1.73m2 (CKD-EPI)
-
Severe hepatic insufficiency (Child-Pugh stage C score)
-
Legal incapacity or limited legal capacity
-
Subject unlikely to cooperate with the study and / or weak cooperation anticipated by the investigator
-
Patient within the exclusion period of another study or planned by the "national file of volunteers"
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Centre Hospitalier Universitaire de Besancon
Investigators
- Principal Investigator: Gaël PITON, MD, CHU de Besancon
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- P/2018/353